Drugs / Palbociclib
Palbociclib
also known as
PD-0332991 · Ibrance · palbociclib, PD-0332991 · PAL · Palbociclib isethiolate · palbociclib isethionate · PALBOCICLIBPD-0332991PD0332991IBRANCECS-0019A-1030 · PD 0332991-0054 · +3 more
Small molecule targets CDK4, CDK6, RB1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 12 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (10) | US (FDA) | IBRANCE | — | 2016-02-19 – 2026-06-24 | fda.gov ↗ |
| Approved | EU (EMA) | Ibrance | — | 2016-11-09 | europa.eu ↗ |
| Approved | US (FDA) | IBRANCE | — | 2015-02-03 | fda.gov ↗ |
Trials 293 · started per year
today
US approved 2015
EU approved 2016
1
1
2
1
3
5
5
11
22
26
23
35
25
24
21
19
16
19
16
14
3
200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 05 trials | ||||||
| Phase 0 | NCT06959979 | Nov 2024 → Aug 2026 overdue | childhood medulloblastoma | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Recruiting | No outcome recorded |
| Phase 0 | NCT04870034 | Jan 2024 → Sep 2025 | colorectal carcinoma, lung adenocarcinoma | Roswell Park Cancer Institute | Withdrawn | No outcome recorded |
| Phase 0 | NCT05432518 | Jun 2023 → Jul 2027 expected | adult glioblastoma | AHS Cancer Control Alberta | Recruiting | No outcome recorded |
| Phase 0 | NCT05238831 | Jan 2023 → May 2026 | female breast carcinoma, ovarian carcinoma, pancreatic ductal adenocarcinoma, pancreatic large cell neuroendocrine carcinoma +2 | OHSU Knight Cancer Institute | Withdrawn | No outcome recorded |
| Phase 0 | NCT04130152 | Nov 2019 → Jan 2022 | breast cancer | SOLTI Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 179 trials | ||||||
| Phase 1 | NCT06654297 | Oct 2024 → Jun 2025 overdue | esophageal squamous cell carcinoma | West China Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06113809 | Feb 2024 → Jul 2028 expected | sarcoma | John Rieth | Recruiting | No outcome recorded |
| Phase 1 | NCT05655598 | Sep 2023 → Aug 2024 | endometrial cancer, female breast carcinoma, refractory malignant neoplasm, small cell lung carcinoma +2 | Brown University | Withdrawn | No outcome recorded |
| Phase 1 | NCT05627232 | Aug 2023 → Jan 2028 expected | acute myeloid leukemia | Thomas Jefferson University | Recruiting | No outcome recorded |
| Phase 1 | NCT05759949 | Mar 2023 → Mar 2025 | PIK3CA-related overgrowth spectrum, hormone receptor-positive breast cancer | Relay Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06307249 | Feb 2023 → Dec 2025 overdue | breast cancer, colorectal cancer, lung cancer, ovarian cancer | Lebanese University | Recruiting | No outcome recorded |
| Phase 1 | NCT05238922 | Jul 2022 → Jul 2027 expected | cancer | Incyte Corporation | Recruiting | No outcome recorded |
| Phase 1 | NCT05293964 | May 2022 → Dec 2024 overdue | breast cancer | Jiangsu Simcere Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05178888 | Jan 2022 → Jun 2023 | cancer or benign tumor | Mirati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05216432 | Dec 2021 → Apr 2027 expected | Her2-receptor negative breast cancer, PIK3CA-related overgrowth spectrum | Relay Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT04818632 | Nov 2021 → Sep 2023 | estrogen-receptor positive breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06570031 | Nov 2021 → Apr 2026 | hormone receptor-positive breast cancer | Ono Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04996160 | Jul 2021 → Oct 2023 | childhood acute lymphoblastic leukemia | Tanja Andrea Gruber | Completed | No outcome recorded |
| Phase 1 | NCT04498520 | Mar 2021 → Jun 2025 | endometrioid adenocarcinoma, fallopian tube carcinoma, female breast carcinoma, hormone receptor-positive breast cancer +4 | Pamela Munster | Withdrawn | No outcome recorded |
| Phase 1 | NCT04693468 | Dec 2020 → Dec 2027 expected | high grade malignant neoplasm, metastatic malignant neoplasm | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT04483505 | Nov 2020 → Apr 2023 | hormone receptor-positive breast cancer | CRIS Cancer Foundation | Completed | No outcome recorded |
| Phase 1 | NCT03685331 | Oct 2020 → Aug 2025 | BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, breast cancer | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 1 | NCT04360941 | Aug 2020 → Jul 2027 expected | HER2 positive breast carcinoma, estrogen-receptor positive breast cancer, female breast carcinoma, triple-negative breast carcinoma | Royal Marsden NHS Foundation Trust | Recruiting | No outcome recorded |
| Phase 1 | NCT04585724 | Jun 2020 → Sep 2021 | female breast carcinoma, metastatic malignant neoplasm in the brain | Emory University | Withdrawn | No outcome recorded |
| Phase 1 | NCT04288089 | Apr 2020 → Sep 2022 overdue | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer | Eisai Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03878524 | Apr → Dec 2020 | acute myeloid leukemia, atypical chronic myeloid leukemia, BCR-ABL1 negative, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, castration-resistant prostate carcinoma +14 | OHSU Knight Cancer Institute | Terminated | No outcome recorded |
| Phase 1 | NCT04185883 | Dec 2019 → Dec 2026 expected | cancer | Amgen | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03900884 | Sep 2019 → Jun 2025 overdue | breast neoplasm | Peter MacCallum Cancer Centre, Australia | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03959891 | May 2019 → Dec 2022 overdue | breast cancer | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03792256 | Apr 2019 → Jun 2021 | T lymphoblastic leukemia/lymphoma, T-cell acute lymphoblastic leukemia, lymphoblastic lymphoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 1 | NCT03854903 | Apr 2019 → Nov 2023 | hormone receptor-positive breast cancer | Georgetown University | Completed | No outcome recorded |
| Phase 1 | NCT06065592 | Feb 2019 → Dec 2024 | breast cancer, colorectal cancer, hepatocellular carcinoma, immune system disorder +4 | Lebanese University | Unknown | No outcome recorded |
| Phase 1 | NCT03616587 | Oct 2018 → Sep 2024 overdue | estrogen-receptor positive breast cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03498378 | Jun 2018 → Feb 2020 overdue | head and neck squamous cell carcinoma | Kathryn Gold | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03455270 | May 2018 → Sep 2022 | breast ductal adenocarcinoma, female breast carcinoma | G1 Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03472573 | May 2018 → Aug 2021 | B-cell acute lymphoblastic leukemia | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 1 | NCT03515200 | Apr 2018 → Jul 2020 | acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Terminated | No outcome recorded |
| Phase 1 | NCT03454035 | Jan 2018 → Jul 2026 overdue | malignant pancreatic neoplasm, melanoma | UNC Lineberger Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT03332797 | Nov 2017 → Jul 2027 expected | breast cancer | Genentech, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03284723 | Nov 2017 → Aug 2021 | breast neoplasm | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT03065387 | Oct 2017 → Oct 2028 expected | metastatic malignant neoplasm, refractory malignant neoplasm | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03238196 | Aug 2017 → Apr 2021 | breast cancer | Vanderbilt-Ingram Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT03128619 | Aug 2017 → Mar 2022 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, invasive breast carcinoma, progesterone-receptor positive breast cancer | Jonsson Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT03132454 | Jul 2017 → Dec 2027 expected | acute lymphoblastic leukemia, acute myeloid leukemia | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03220191 | Jul → Sep 2017 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03170206 | May 2017 → Feb 2023 | lung cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT03065062 | Feb 2017 → Dec 2026 | head and neck cancer, malignant pancreatic neoplasm, squamous cell lung carcinoma | Dana-Farber Cancer Institute | Suspended | No outcome recorded |
| Phase 1 | NCT03006172 | Dec 2016 → Dec 2026 expected | breast cancer | Genentech, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02897375 | Oct 2016 → Oct 2021 | cancer of unknown primary site, colorectal cancer, female breast carcinoma, head and neck cancer +5 | Emory University | Completed | No outcome recorded |
| Phase 1 | NCT02684032 | Jun 2016 → Jan 2022 | breast cancer | Celcuity Inc | Completed | No outcome recorded |
| Phase 1 | NCT02626507 | Jan 2016 → Feb 2022 | breast cancer | Hoffman Oncology | Unknown | No outcome recorded |
| Phase 1 | NCT02599714 | Dec 2015 → Mar 2018 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02501902 | Nov 2015 → Oct 2018 | pancreatic ductal adenocarcinoma | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02499146 | Sep 2015 → Jul 2018 | female breast carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02334800 | Mar 2015 → Oct 2016 | liver disorder | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02389842 | Mar 2015 → Oct 2018 | breast cancer | Royal Marsden NHS Foundation Trust | Completed | No outcome recorded |
| Phase 1 | NCT02311946 | Jan → Apr 2015 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02255461 | Dec 2014 → Feb 2019 | anaplastic astrocytoma, anaplastic oligodendroglioma, childhood brain stem glioma, childhood cerebellar astrocytic neoplasm +11 | Pediatric Brain Tumor Consortium | Terminated | No outcome recorded |
| Phase 1 | NCT02222441 | Oct → Dec 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02159755 | Aug 2014 → Jun 2018 overdue | mantle cell lymphoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02131298 | May → Jun 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02085538 | May 2014 → May 2016 | impaired renal function disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02065063 | Apr 2014 → Jun 2016 | cancer | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02097329 | Apr → Jun 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02059330 | Mar → Jun 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02083640 | Mar → May 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02030483 | Feb 2014 → Jul 2016 | plasma cell myeloma | Weill Medical College of Cornell University | Terminated | No outcome recorded |
| Phase 1 | NCT01976169 | Jan 2014 → May 2021 | breast cancer | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT02041273 | Jan → Mar 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02022982 | Jan 2014 → Nov 2017 | lung cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT01953731 | Oct 2013 → Jan 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01918176 | Sep → Dec 2013 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01906125 | Sep 2013 → Jan 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01904747 | Jul → Oct 2013 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01756781 | May → Jul 2013 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01802476 | May → Jun 2013 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01821066 | Apr → Aug 2013 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01701375 | Sep 2012 → Apr 2013 | myelodysplastic syndrome | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 1 | NCT01602887 | May → Nov 2012 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01522989 | Dec 2011 → Dec 2020 | high grade malignant neoplasm | Georgetown University | Unknown | No outcome recorded |
| Phase 1 | NCT01320592 | Mar 2011 → May 2019 | breast cancer | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 1 | NCT01111188 | Aug 2010 → Feb 2013 | mantle cell lymphoma | Weill Medical College of Cornell University | Terminated | No outcome recorded |
| Phase 1 | NCT00420056 | May 2007 → Mar 2010 | mantle cell lymphoma | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00141297 | Sep 2004 → Jul 2008 | non-Hodgkin lymphoma | Pfizer | Completed | No outcome recorded |
| Phase 1/239 trials | ||||||
| Phase 1/2 | NCT06753747 | Sep 2025 → Sep 2027 expected | esophageal cancer | West China Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06947811 | Jun 2025 → Mar 2027 expected | CDK4 linked melanoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07002177 | Jun 2025 → May 2028 expected | estrogen-receptor positive breast cancer | Forward Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06843967 | Feb 2025 → Aug 2028 expected | dedifferentiated liposarcoma, myxoid liposarcoma, pleomorphic liposarcoma, round cell liposarcoma +1 | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06757335 | Jan 2025 → Jan 2026 overdue | breast cancer | Hinova Pharmaceuticals Inc. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06895733 | Nov 2024 → Dec 2025 overdue | cancer | Tianjin Medical University Second Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06364956 | May 2024 → Jun 2026 overdue | urinary bladder cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05665361 | Apr 2024 → Jun 2027 expected | clear cell renal carcinoma, papillary renal cell carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06188520 | Dec 2023 → Aug 2027 expected | estrogen-receptor positive breast cancer, ovarian serous adenocarcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05953350 | Nov 2023 → May 2024 overdue | — | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05867251 | Aug 2023 → Jan 2028 expected | endometrial cancer, fallopian tube cancer, hormone receptor-positive breast cancer, malignant epithelial tumor of ovary +2 | Avenzo Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05563220 | Jan 2023 → Dec 2026 expected | breast cancer | Stemline Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05468697 | Aug 2022 → Jul 2026 overdue | renal cell carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06940349 | Oct 2021 → Jan 2026 overdue | refractory malignant neoplasm | Rabin Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05039177 | Sep 2021 → Aug 2025 | colorectal cancer, pancreatic ductal adenocarcinoma | Erasca, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT04669587 | Jul 2021 → Jan 2023 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer | EnhancedBio USA Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04802759 | Jun 2021 → May 2029 expected | estrogen-receptor positive breast cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04494958 | Nov 2020 → Dec 2023 | triple-negative breast carcinoma | Fundacion Oncosur | Completed | No outcome recorded |
| Phase 1/2 | NCT04720768 | Jun 2020 → Dec 2024 | melanoma, metastatic neoplasm | Peter MacCallum Cancer Centre, Australia | Unknown | No outcome recorded |
| Phase 1/2 | NCT04072952 | Aug 2019 → Sep 2024 | breast cancer | Arvinas Estrogen Receptor, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03965845 | Jun 2019 → Sep 2021 | non-small cell lung carcinoma | Calithera Biosciences, Inc | Completed | No outcome recorded |
| Phase 1/2 | NCT03844997 | Jun 2019 → Jan 2024 | acute myeloid leukemia | Sudipto Mukherjee, MD, PhD, MPH | Completed | No outcome recorded |
| Phase 1/2 | NCT03560531 | Nov 2018 → Apr 2022 | breast cancer | Zeno Alpha Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03709082 | Oct 2018 → Mar 2020 | HER2 positive breast carcinoma | University of Kansas Medical Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT03158389 | May 2018 → Feb 2023 | adult glioblastoma | University Hospital Heidelberg | Completed | No outcome recorded |
| Phase 1/2 | NCT03424005 | Mar 2018 → Sep 2030 expected | breast cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03304080 | Dec 2017 → Jul 2026 overdue | breast neoplasm | Icahn School of Medicine at Mount Sinai | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03386929 | Nov 2017 → Dec 2022 | non-small cell lung carcinoma | Worldwide Innovative Network Association | Terminated | No outcome recorded |
| Phase 1/2 | NCT03054363 | Nov 2017 → Jan 2023 | breast cancer | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 1/2 | NCT03284957 | Sep 2017 → Nov 2024 | breast cancer | Sanofi | Terminated | No outcome recorded |
| Phase 1/2 | NCT03024489 | Jul 2017 → Mar 2024 | head and neck squamous cell carcinoma | Mahidol University | Unknown | No outcome recorded |
| Phase 1/2 | NCT02871791 | Aug 2016 → Dec 2020 | hormone receptor-positive breast cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT02605486 | Nov 2015 → Nov 2026 expected | breast cancer | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02448771 | Jul 2015 → Aug 2019 | invasive breast carcinoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT02310243 | Jul 2015 → Jul 2019 | acute lymphoblastic leukemia, acute myeloid leukemia | University of Ulm | Unknown | No outcome recorded |
| Phase 1/2 | NCT02349633 | May 2015 → May 2020 | non-small cell lung carcinoma | Pfizer | Terminated | No outcome recorded |
| Phase 1/2 | NCT01823835 | Dec 2014 → Mar 2020 | breast cancer | Genentech, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT02101034 | Jun 2014 → Jun 2020 | head and neck squamous cell carcinoma | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT02202200 | May 2014 → Nov 2016 | melanoma | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| Phase 2131 trials | ||||||
| Phase 2 | NCT07527806 | May 2026 → May 2029 expected | breast cancer | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07191977 | Jan 2026 → Dec 2027 expected | esophageal squamous cell carcinoma | West China Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07300215 | Dec 2025 → Nov 2027 expected | breast cancer | The First Affiliated Hospital of Bengbu Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07299890 | Dec 2025 → Nov 2027 expected | breast cancer | Anhui Provincial Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07123090 | Nov 2025 → Oct 2026 expected | clear cell renal carcinoma | Stephanie Berg | Recruiting | No outcome recorded |
| Phase 2 | NCT07037199 | Aug 2025 → Jun 2028 expected | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06692491 | Jan 2025 → Dec 2027 expected | — | Peking University Shenzhen Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07130643 | Dec 2024 → Dec 2026 expected | hormone receptor-positive breast cancer | Xinhong Wu, PhD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06739395 | Nov 2024 → Dec 2026 expected | cancer | Tianjin Medical University Second Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05176288 | May 2024 → Aug 2026 | clear cell renal carcinoma | Bradley A. McGregor, MD | Withdrawn | No outcome recorded |
| Show all 131 trials opens the full record — a long page | ||||||
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT02692755 | Sep 2016 → Dec 2019 | hormone receptor-positive breast cancer | Georgetown University | Completed | No outcome recorded |
| Phase 2/3 | NCT02785939 | Sep 2014 → Jun 2017 | non-small cell squamous lung carcinoma | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 326 trials | ||||||
| Phase 3 | NCT07683754 | Sep 2026 → Jul 2030 expected | HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer | Daiichi Sankyo | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06757634 | Jul 2025 → Mar 2029 expected | breast cancer | Celcuity Inc | Recruiting | No outcome recorded |
| Phase 3 | NCT07005557 | Jun 2025 → May 2030 expected | breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06377852 | Oct 2024 → Aug 2028 expected | breast cancer | American Society of Clinical Oncology | Recruiting | No outcome recorded |
| Phase 3 | NCT06380751 | Aug 2024 → Mar 2029 expected | female breast carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06044623 | Apr 2024 → Oct 2028 expected | breast cancer | Region Örebro County | Recruiting | No outcome recorded |
| Phase 3 | NCT05909397 | Aug 2023 → Dec 2026 expected | breast cancer | Pfizer | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05501886 | Dec 2022 → Jun 2026 overdue | breast cancer | Celcuity Inc | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04966481 | Apr 2022 → Feb 2028 expected | head and neck squamous cell carcinoma | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 3 | NCT05207709 | Mar 2022 → Mar 2026 | breast cancer | SOLTI Breast Cancer Research Group | Terminated | No outcome recorded |
| Phase 3 | NCT04862663 | May 2021 → Nov 2027 expected | Her2-receptor negative breast cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT05429684 | Jan 2021 → Feb 2024 | HER2 positive breast carcinoma | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase 3 | NCT04478266 | Oct 2020 → Jun 2022 | breast cancer | Sanofi | Terminated | No outcome recorded |
| Phase 3 | NCT03784014 | Oct 2019 → Dec 2023 | soft tissue sarcoma | French National Institute of Health and Medical Research | Completed | No outcome recorded |
| Phase 3 | NCT04047758 | Sep 2019 → Sep 2021 | breast cancer | Shengjing Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03820830 | Aug 2019 → Jul 2026 overdue | breast cancer | ETOP IBCSG Partners Foundation | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03423199 | Feb 2018 → Sep 2025 | breast cancer | National Cancer Center, Japan | Unknown | No outcome recorded |
| Phase 3 | NCT02947685 | Jun 2017 → Oct 2024 overdue | HER2 positive breast carcinoma, estrogen-receptor positive breast cancer | Alliance Foundation Trials, LLC. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03079011 | Mar 2017 → Apr 2021 | breast cancer | UNICANCER | Completed | No outcome recorded |
| Phase 3 | NCT02600923 | Apr 2016 → May 2019 | female breast carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT02513394 | Aug 2015 → Nov 2020 overdue | breast cancer | Alliance Foundation Trials, LLC. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02297438 | Mar 2015 → Aug 2020 | breast neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT02028507 | Mar 2014 → Jan 2019 | breast cancer | Spanish Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 3 | NCT01864746 | Oct 2013 → Aug 2020 | hormone receptor-positive breast cancer | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 3 | NCT01942135 | Sep 2013 → Dec 2014 | breast cancer | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01740427 | Feb 2013 → Feb 2016 | breast cancer | Pfizer | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT05691400 | Mar 2024 → Mar 2027 | leukodystrophy, hypomyelinating, 22 | University of Michigan Rogel Cancer Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT04137640 | Jul 2021 → Nov 2025 | breast cancer | Shengjing Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03355157 | Mar 2018 → Aug 2024 | breast cancer | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 4 | NCT02679755 | Mar 2016 → Jul 2019 | female breast carcinoma | Pfizer | Completed | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT06810492 | Apr → Dec 2025 overdue | female breast carcinoma | Hongmei Zheng, PhD | Not yet recruiting | No outcome recorded |
| — | NCT06856200 | Feb → Oct 2025 overdue | Her2-receptor negative breast cancer, hormone-resistant breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| — | NCT06478927 | Jan 2024 → Jan 2026 overdue | hepatocellular carcinoma | Henan Cancer Hospital | Recruiting | No outcome recorded |
| — | NCT04801966 | Sep 2021 → Dec 2022 | cancer | Peter MacCallum Cancer Centre, Australia | Terminated | No outcome recorded |
| — | NCT03756090 | Dec 2018 → Dec 2019 | breast cancer | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| — | NCT05063058 | Jan 2016 → Nov 2019 | melanoma | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT02142868 | — | Her2-receptor negative breast cancer | Pfizer | No longer available | No outcome recorded |
Also used as a comparator or background therapy in 45 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02913430 Comparator | Apr 2018 → Apr 2022 | breast cancer | Shannon Puhalla | Completed | No outcome recorded |
| Phase 19 trials | ||||||
| Phase 1 | NCT06997029 Background | Aug 2025 → Dec 2028 expected | breast cancer, ovarian cancer | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 1 | NCT06941142 Background | Apr 2025 → Oct 2027 expected | breast cancer | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05683418 Background | Feb 2023 → Dec 2027 expected | hormone receptor-positive breast cancer | Totus Medicines | Recruiting | No outcome recorded |
| Phase 1 | NCT05384119 Background | Jan 2023 → Apr 2024 | female breast carcinoma | Tvardi Therapeutics, Incorporated | Terminated | No outcome recorded |
| Phase 1 | NCT05266105 Background | Dec 2021 → Mar 2026 overdue | breast cancer | Olema Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04872608 Background | Sep 2021 → Apr 2023 | breast carcinoma, metastatic neoplasm | Memorial Sloan Kettering Cancer Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT04856371 Background | Apr 2021 → Mar 2022 | breast cancer | Haihe Biopharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04060862 Background | Nov 2019 → Aug 2023 | breast cancer | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1 | NCT03471663 Background | Mar 2018 → Oct 2023 | breast cancer | InventisBio Co., Ltd | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT07173556 Background | Sep 2025 → Feb 2027 expected | breast cancer | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06736704 Background | Feb 2025 → Apr 2027 expected | cancer | Pikavation Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05768139 Background | Apr 2023 → Jul 2030 expected | breast cancer | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04946864 Background | Aug 2021 → Aug 2024 | breast cancer | Ascentage Pharma Group Inc. | Suspended | No outcome recorded |
| Phase 1/2 | NCT03774472 Background | Aug 2018 → Apr 2024 | female breast carcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 213 trials | ||||||
| Phase 2 | NCT07180160 Background | Sep 2025 → Sep 2027 expected | female breast carcinoma | Wenjin Yin | Recruiting | No outcome recorded |
| Phase 2 | NCT06486883 Comparator | Jun 2025 → Jan 2027 expected | hormone receptor-positive breast cancer | MedSIR | Recruiting | No outcome recorded |
| Phase 2 | NCT06207734 Comparator | Jan 2024 → Jan 2027 expected | breast cancer | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Recruiting | No outcome recorded |
| Phase 2 | NCT06176534 Comparator | Jan 2024 → Dec 2025 overdue | Her2-receptor negative breast cancer, female breast carcinoma | Henan Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04920708 Background | Dec 2022 → Jun 2027 expected | estrogen-receptor positive breast cancer | Royal Marsden NHS Foundation Trust | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04819243 Background | Aug 2021 → Dec 2025 overdue | hormone receptor-positive breast cancer | Samsung Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04563507 Comparator | Nov 2020 → Oct 2027 expected | breast cancer | Weill Medical College of Cornell University | Recruiting | No outcome recorded |
| Phase 2 | NCT04220476 Comparator | Mar 2020 → Dec 2025 | breast cancer | Weill Medical College of Cornell University | Withdrawn | No outcome recorded |
| Phase 2 | NCT03819010 Comparator | May → Jul 2019 | breast cancer | MedSIR | Completed | No outcome recorded |
| Phase 2 | NCT03573648 Comparator | Nov 2018 → Sep 2026 expected | breast cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03377101 Background | Aug 2018 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, progesterone-receptor positive breast cancer | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 2 | NCT03227328 Comparator | Aug 2017 → Feb 2022 | hormone receptor-positive breast cancer | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Completed | No outcome recorded |
| Phase 2 | NCT02630693 Comparator | Apr 2016 → Aug 2018 | breast cancer | Canadian Cancer Trials Group | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04191499 Background | Jan 2020 → Sep 2023 overdue | breast cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 312 trials | ||||||
| Phase 3 | NCT07492641 Comparator | May 2026 → Apr 2029 expected | hormone receptor-positive breast cancer | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 3 | NCT07174336 Background | Dec 2025 → May 2029 expected | breast cancer, metastatic neoplasm | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT07061717 Comparator | Jul 2025 → Jul 2029 expected | hormone receptor-positive breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06760637 Comparator | Jan 2025 → Jan 2029 expected | breast cancer | Pfizer | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06065748 Background | Dec 2023 → Feb 2027 expected | estrogen-receptor positive breast cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 3 | NCT05670054 Comparator | Mar 2022 → Oct 2023 | female breast carcinoma | Mansoura University | Unknown | No outcome recorded |
| Phase 3 | NCT04964934 Background | Jun 2021 → Jun 2025 overdue | estrogen-receptor positive breast cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04711252 Background | Jan 2021 → Aug 2026 overdue | estrogen-receptor positive breast cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04546009 Background | Oct 2020 → Jan 2026 overdue | estrogen-receptor positive breast cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03969121 Comparator | Jul 2019 → Dec 2021 | female breast carcinoma, hormone receptor-positive breast cancer | Kyoto Breast Cancer Research Network | Completed | No outcome recorded |
| Phase 3 | NCT03447132 Comparator | Dec 2017 → Apr 2021 | breast cancer | International Cancer Research Group, United Arab Emirates | Completed | No outcome recorded |
| Phase 3 | NCT03425838 Comparator | Nov 2017 → Mar 2023 overdue | breast cancer | Dutch Breast Cancer Research Group | Active not recruiting | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT07487129 Comparator | Aug 2024 → Oct 2025 | breast cancer | Beni-Suef University | Completed | No outcome recorded |
| Phase 4 | NCT05949424 Comparator | May 2024 → Mar 2025 | breast carcinoma, endometrial carcinoma, ovarian carcinoma, renal cell carcinoma +1 | University Medical Center Groningen | Unknown | No outcome recorded |
| Phase 4 | NCT03220178 Background | Jul 2017 → Dec 2021 | breast cancer | Palleos Healthcare GmbH | Terminated | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03870919 Background | Oct 2019 → Aug 2024 overdue | female breast carcinoma | UNICANCER | Active not recruiting | No outcome recorded |
Press releases naming this drug 29 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-24 | Pfizer | FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance pfizer.com ↗ |
| 2024-12-12 | Pfizer | Pfizer’s IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer pfizer.com ↗ |
| 2022-06-04 | Pfizer | Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE® (palbociclib) for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancer pfizer.com ↗ |
| 2021-09-19 | Novartis Pharmaceuticals | Novartis announces collaboration on HARMONIA, a Phase III, head-to-head trial evaluating Kisqali® vs. Ibrance®* in patients with HR+/HER2- advanced breast cancer novartis.com ↗ |
| 2021-03-25 | Pfizer | Real-World Evidence Supports Effectiveness of First-line IBRANCE® (palbociclib) Combination Therapy in HR+, HER2- Metastatic Breast Cancer pfizer.com ↗ |
| 2021-02-05 | Pfizer | Pfizer Confirms U.S. Patent Term Extension for IBRANCE® (palbociclib) Until March 2027 pfizer.com ↗ |
| 2020-10-09 | Pfizer | PENELOPE-B Trial of IBRANCE® (palbociclib) in Early Breast Cancer Did Not Meet Primary Endpoint pfizer.com ↗ |
| 2020-05-29 | Pfizer | Pfizer Provides Update on Phase 3 PALLAS Trial of IBRANCE® (palbociclib) Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer pfizer.com ↗ |
| 2019-09-24 | Pfizer | Pfizer Presents New Evidence of IBRANCE® (palbociclib) Effectiveness in HR+, HER2- Metastatic Breast Cancer Patients in Four Real-World Studies at ESMO Congress 2019 pfizer.com ↗ |
| 2019-04-04 | Pfizer | U.S. FDA Approves IBRANCE® (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer pfizer.com ↗ |
| 2018-10-20 | Pfizer | Pfizer Presents Overall Survival Data From PALOMA-3 Trial of IBRANCE® (palbociclib) in Patients With HR+, HER2- Metastatic Breast Cancer pfizer.com ↗ |
| 2018-06-25 | Pfizer | Pfizer Announces Overall Survival Results from Phase 3 PALOMA-3 Trial of IBRANCE® (Palbociclib) in HR+, HER2- Metastatic Breast Cancer pfizer.com ↗ |
| 2017-12-06 | Pfizer | Updated Data from Phase 3 Trial of IBRANCE® (palbociclib) Plus Letrozole in ER+, HER2- Metastatic Breast Cancer Confirm Improvement in Progression-Free Survival pfizer.com ↗ |
| 2017-08-22 | Pfizer | Alliance Foundation Trials Opens Global Trial Investigating First-in-Class Palbociclib in HR+, HER2+ Metastatic Breast Cancer pfizer.com ↗ |
| 2017-03-31 | Pfizer | IBRANCE® (palbociclib) Receives FDA Regular Approval and Expanded Indication for First-Line HR+, HER2- Metastatic Breast Cancer pfizer.com ↗ |
| 2016-12-21 | Pfizer | FDA Accepts Supplemental New Drug Application for Pfizer’s IBRANCE® (palbociclib) in HR+, HER2- Metastatic Breast Cancer pfizer.com ↗ |
| 2016-12-19 | Pfizer | Pfizer Presents Data from PALOMA-2 Phase 3 Study Demonstrating Clinical Benefit of IBRANCE® (palbociclib) in Asian Women with ER+, HER2- Metastatic Breast Cancer at ESMO Asia Congress pfizer.com ↗ |
| 2016-11-16 | Pfizer | PALOMA-2 Phase 3 Study Published In The New England Journal Of Medicine Demonstrates Clinical Benefit Of Pfizer’s IBRANCE® (palbociclib) In First-Line ER+, HER2- Metastatic Breast Cancer pfizer.com ↗ |
| 2016-11-09 | Pfizer | IBRANCE® (palbociclib) Receives Approval in European Union for the Treatment of Women with HR+/HER2- Metastatic Breast Cancer pfizer.com ↗ |
| 2016-09-16 | Pfizer | Pfizer Receives Positive CHMP Opinion For IBRANCE® (palbociclib) In Combination With Endocrine Therapy For The Treatment Of HR+/HER2- Metastatic Breast Cancer In Europe pfizer.com ↗ |
| 2016-04-19 | Pfizer | Pfizer Announces Positive Top-Line Results for Phase 3 PALOMA-2 Clinical Trial of IBRANCE® (palbociclib) pfizer.com ↗ |
| 2016-02-19 | Pfizer | Pfizer Receives Expanded FDA Approval For IBRANCE (palbociclib) In HR+, HER2- Metastatic Breast Cancer pfizer.com ↗ |
| 2015-12-10 | Pfizer | Pfizer Announces FDA Acceptance of IBRANCE® (palbociclib) Supplemental New Drug Application with Priority Review in HR+, HER2- Metastatic Breast Cancer pfizer.com ↗ |
| 2015-08-26 | Pfizer | Alliance Foundation Trials and Austrian Breast & Colorectal Cancer Study Group Open Largest Global Phase 3 Trial of Targeted Therapy, IBRANCE® (palbociclib), for Patients with Hormone Receptor–Positive Early Breast Cancer pfizer.com ↗ |
| 2015-08-20 | Pfizer | Pfizer Announces European Medicines Agency Validates Marketing Authorization Application for IBRANCE® (palbociclib) in Combination with Endocrine Therapy for the Treatment of HR+/HER2- Metastatic Breast Cancer pfizer.com ↗ |
| 2015-05-30 | Pfizer | Pfizer Announces Palbociclib More Than Doubled Progression-Free Survival in Phase 3 Trial for Patients With HR+, HER2- Metastatic Breast Cancer Whose Disease Has Progressed Following Endocrine Therapy pfizer.com ↗ |
| 2015-04-15 | Pfizer | Pfizer Announces PALOMA-3 Trial For IBRANCE® (Palbociclib) Stopped Early Due To Efficacy Seen In Patients With HR+, HER2- Metastatic Breast Cancer Whose Disease Has Progressed Following Endocrine Therapy pfizer.com ↗ |
| 2015-02-03 | Pfizer | Pfizer Receives U.S. FDA Accelerated Approval of IBRANCE® (palbociclib) pfizer.com ↗ |
| 2015-01-08 | Pfizer | Pfizer Provides Update on IBRANCE® (palbociclib) pfizer.com ↗ |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 342 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Palbociclib | “Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 with preclinical evidence of growth-inhibitory activity in oestrogen...” PMID 25524798 ↗ Dec 2014319“Full initial dose of either one of the CDK 4/6-inhibitors: Palbociclib 125 mg x 1 for 21 days with 7 days off; or Ribociclib 600 mg x 1 for 21 days with 7 days off; or...” NCT06044623 ↗ “Palbociclib is a highly selective, reversible, oral inhibitor of cyclin-dependent kinases 4 and 6 that is approved to treat hormone receptor-positive/human epidermal growth...” PMID 32420697 ↗ May 2020 “Cyclin dependant kinase inhibitors (CDK inhibitors) mainly Palbociclib (PAL), ribociclib (RIB) and abemaciclib (ABM) are approved for treatment of hormone receptor positive,...” NCT05670054 ↗ “A Drug-Drug Interaction Study To Investigate The Potential For Multiple Doses Of Palbociclib (PD-0332991) To Alter The Pharmacokinetics Of Oral Midazolam In Adult Healthy Women...” NCT01756781 ↗ “Patient receive standard endocrine therapy (ETH) in combination with Palbociclib. palbociclib administered according to standard dosing regimen (125mg /day ) for 3 consecutive...” NCT07487129 ↗ “Palbociclib is an investigational (experimental) drug that works to induce early G1 arrest by inhibiting CDK4/6, which are two types of CDKs that are overexpressed in AML cell...” NCT03844997 ↗ “An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.” NCT00420056 ↗ “Phase I-II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAF (V600MUT) Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism.” PMID 33947696 ↗ May 2021 “Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.” PMID 25813205 ↗ May 2015 “A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)” NCT01740427 ↗ “Palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, blocks proliferation in a RB and cyclin D-dependent manner in preclinical prostate cancer models.” PMID 33727260 ↗ Mar 2021 “A Study Comparing the Plasma Drug Exposure of an Oral Dose of Palbociclib (PD-0332991) to an Intravenous Dose of Palbociclib (PD-0332991)” NCT01802476 ↗ “sequential Trastuzumab rezetecan followed by CDK4/6 inhibitors (Dalpiciclib, Abemaciclib, Ribociclib, Palbociclib) plus endocrine therapy” NCT07037199 ↗ “the neoadjuvant treatment regimen of trastuzumab dual-target combined with exemestane and palbociclib for 4 cycles.” NCT07300215 ↗ “Palbociclib is a highly selective, reversible oral inhibitor of cyclin-dependent kinases (CDK) 4 and 6.” NCT05665361 ↗ “physician's choice of CDK4/6 inhibitor (CDK4/6i) including palbociclib, ribociclib, and abemaciclib” NCT06486883 ↗ “All patients will receive CDK4/6 inhibitor (abemaciclib/ribociclib/dalpiciclib/palbociclib)” NCT07005557 ↗ “Drug: Palbociclib 125mg, orally, once a day concomitantly with ulixertinib” NCT03454035 ↗ “Palbociclib 125 mg once a day in3 weeks, hereafter pause for one week” NCT04644432 ↗ “CDK4/6 inhibitors：dalpiciclib,palbociclib,abemaciclib,ribociclib” NCT07130643 ↗ “CDK4/6 inhibitor: * palbociclib * ribociclib * abemaciclib” NCT03227328 ↗ “palbociclib,Ibrance,ribociclib,Kisqali,abemaciclib,Verzenio” NCT03425838 ↗ “palbociclib OR ribociclib OR abemaciclib OR dalpiciclib” NCT07180160 ↗ “CDK4/6 inhibitors: Palbociclib, Abemaciclib, Ribociclib” NCT07173556 ↗ “* CDK4/6i: Palbociclib, Ribociclib or Abemaciclib” NCT05826964 ↗ “Cell cycle Inhibitor (Palbociclib 125 mg/d)” NCT05063058 ↗ “Palbociclib 125mg once daily every 21days” NCT07527806 ↗ “palbociclib 125mg per day for 21days” NCT06176534 ↗ “Palbociclib (125mg, po, qd)” NCT05429684 ↗ “Palbociclib 125mg po D1-21” NCT04819243 ↗ “palbociclib 125 mg PO qd” NCT06145308 ↗ |
| Known as | Ibrance | “Palbociclib (IBRANCE®) is a kinase inhibitor FDA approved for the following indications: treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor...” NCT06843967 ↗8“This phase I study estimated the effect of food on bioavailability of palbociclib (IBRANCE®), and a selective inhibitor of cyclin-dependent kinase 4/6 approved for oncology...” PMID 28204912 ↗ Feb 2017 “(1) Palbociclib (trade name: Ibrance®; Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany; imported drug license No. H20180040): 125 mg/capsule, 1 capsule by mouth once a day” NCT04047758 ↗ “The purpose of this study is to find out what effects, good and/or bad, Palbociclib (Ibrance) (formerly known as PD0332991) has on the patient and on the liposarcoma.” NCT01209598 ↗ “Palbociclib (Ibrance) is an oral capsule or tablet administered once daily with food on Days 1-21 of every 28-day cycle in combination with telaglenestat.” NCT03965845 ↗ “Drug: Palbociclib Participants will receive oral palbociclib on days 1-21 of each 28-day cycle. Other Names: • IBRANCE” NCT06757634 ↗ “Part C: Daily oral dosages of ARV-471 for 28 days in combination with palbociclib (IBRANCE®) for 21 days” NCT04072952 ↗ “Palbociclib (Ibrance) (PO), dose= 125 mg PO daily, days=1-14, cycle length: 21 days” NCT03194373 ↗ “palbociclib (Ibrance®️, Pfizer Inc.)” NCT05266105 ↗ |
| Known as | PAL | “Cyclin dependant kinase inhibitors (CDK inhibitors) mainly Palbociclib (PAL), ribociclib (RIB) and abemaciclib (ABM) are approved for treatment of hormone receptor positive,...” NCT05670054 ↗ |
| Known as | Palbociclib isethiolate | ChEMBL registry synonym — accepted as the source's own label CHEMBL189963 ↗ |
| Known as | palbociclib isethionate | “This phase I trial studies the side effects and best dose of palbociclib isethionate in treating younger patients with central nervous system tumors that have grown, come back,...” NCT02255461 ↗ |
| Known as | palbociclib, PD-0332991 | “palbociclib, PD-0332991” NCT01953731 ↗4“Palbociclib, PD-0332991” NCT02222441 ↗ “palbociclib (PD0332991)” NCT02806648 ↗ “Palbociclib, PD-0332991” NCT02334800 ↗ “Palbociclib=PD-0332991” NCT01976169 ↗ |
| Known as | PALBOCICLIBPD-0332991PD0332991IBRANCECS-0019A-1030 | ChEMBL registry synonym — accepted as the source's own label CHEMBL189963 ↗ |
| Known as | PD 0332991-0054 | ChEMBL registry synonym — accepted as the source's own label CHEMBL189963 ↗ |
| Known as | PD-0332991 | “A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The...” NCT01684215 ↗40“Phase I Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell...” NCT03065062 ↗ “An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.” NCT00420056 ↗ “A Phase 1, Open-Label, 6 Sequence, 3 Period, Crossover Study Of Palbociclib (PD-0332991) In Healthy Volunteers To Estimate The Relative Bioavailability Of 3 Palbociclib Formulations” NCT02083640 ↗ “A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]” NCT02297438 ↗ “The purpose of this study is to find out what effects, good and/or bad, Palbociclib (Ibrance) (formerly known as PD0332991) has on the patient and on the liposarcoma.” NCT01209598 ↗ “A Phase 1, Open-label, Single Dose, Parallel-group Study To Evaluate The Pharmacokinetics Of Palbociclib (Pd-0332991) In Subjects With Impaired Renal Function” NCT02085538 ↗ “A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)” NCT01740427 ↗ “Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)” NCT01942135 ↗ “A Study Comparing the Plasma Drug Exposure of an Oral Dose of Palbociclib (PD-0332991) to an Intravenous Dose of Palbociclib (PD-0332991)” NCT01802476 ↗ “Drug Interaction Study To Investigate The Potential Effect Of Proton Pump Inhibitor On The Pharmacokinetics Of Palbociclib (PD-0332991)” NCT01918176 ↗ “This multicenter phase II trial will evaluate palbociclib (PD-0332991) in patients with metastatic urothelial carcinoma (UC)” NCT02334527 ↗ “A Study To Establish The Equivalence Of 2 Palbociclib (PD-0332991) Formulations To The Intended Final Market Product” NCT01906125 ↗ “Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6” PMID 25524798 ↗ Dec 2014 “PD-0332991 was administrated orally, formulated as gelatin capsules of 100 mg and 25 mg respectively.” NCT01907607 ↗ “neratinib plus palbociclib (PD-0332991) compared to neratinib maleate (neratinib) alone” NCT06126276 ↗ “Relative Bioavailability Of Palbociclib (PD-0332991) Under Fed And Fasted Conditions” NCT02041273 ↗ “Palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor” NCT01864746 ↗ “PD0332991 (Oral CDK 4/6 Inhibitor)” NCT01709370 ↗ “Palbociclib (PD-0332991)” NCT02097329 ↗ “PD-0332991 (Palbociclib)” NCT02690480 ↗ “Palbociclib (PD0332991)” NCT02530320 ↗ |
| Known as | PD-0332991, palbociclib | “PD-0332991, palbociclib” NCT01821066 ↗ |
| Known as | PF-00080665-73 | ChEMBL registry synonym — accepted as the source's own label CHEMBL189963 ↗ |
| Known as | PFE-PKIS 32 | ChEMBL registry synonym — accepted as the source's own label CHEMBL189963 ↗ |
| Action | Inhibit | “PD-0332991 is in a new class of drugs called cyclin-dependent kinase (CDK inhibitors).” NCT00141297 ↗ |
| Modality | Small molecule | “Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 with preclinical evidence of growth-inhibitory activity in oestrogen...” PMID 25524798 ↗ Dec 2014 |
| Route | Oral | “Dose ranging study - evaluating two oral schedule: (1) 3/1 Schedule - PD-0332991 administered days 1-21 of a 28-day schedule, doses ranging from 25 to 150 mg once daily; (2)...” NCT00141297 ↗ |
| Target | CDK4 | “selective CDK4/6 inhibitor PD0332991” PMID 22383795 ↗ Mar 2012 |